These results emphasized the need to elucidate the IDO/kynurenine signal in the sarcoma TME and to refine dosing and combinatorial strategies before deploying IDO pathway inhibitors as clinical biomarkers or therapeutic partners. The gene discussed is IDO1; the disease is sarcoma.